本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的，不可用于人类或动物的临床诊断或者治疗，非药用，非食用。
Abatacept
英文名：Unii-7D0yb67S97
Cas号：332348-12-6
Cas号：332348-12-6
检测信息查询
| 别 名 | Unii-7D0yb67S97 |
| Cas号 | 332348-12-6 |
| M D L | |
| 分子式 | |
| 分子量 | |
| 产品参数 | Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Description Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains)[1]. Abatacept is a selective T-cell co-stimulation modulator and a protein drug for the autoimmune diseases[2]. |
| 性状 | Abatacept (CTLA4lg) 是一种可溶性融合蛋白，由人 CTLA4 的胞外结构域和人 IgG1 Fc 部分的片段 (铰链，CH2 和 3 结构域) 组成。Abatacept 是选择性 T 细胞共刺激调节剂，也是一种用于自身免疫性疾病的蛋白药物。 |
| 贮存 | Storage Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month References [1]. Kiykim A, et al. Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency. J Allergy Clin Immunol Pract. 2019 Jun 22. [2]. Lon HK, et al. Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. J Pharmacokinet Pharmacodyn. 2013 Dec;40(6):701-12. [3]. Patakas A, et al. Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigen-Presenting Cells. Arthritis Rheumatol. 2016 Mar;68(3):627-38. |
- 维多珠单抗 943609-66-3
- 优特克诺 815610-63-0
- 雷莫芦单抗 947687-13-0
- Human IgG1 Control
- Abatacept 332348-12-6
- Obinutuzumab
- Reslizumab 241473-69-8
- 那他珠单抗 189261-10-7
- BENRALIZUMAB 1044511-01-4
沪公网安备 31012002003054号